MQSA: The Unlikely Birth of the Only Imaging Modality with Real Federal Teeth

The most recent amendments to the Mammography Quality Standards Act (MQSA) took effect on September 10, 2024. These updates, issued by the U.S. Food and Drug Administration under the 2023 final rule, require standardized reporting of breast tissue density in both the medical report provided to the referring healthcare provider and the lay summary given to the patient. Facilities must use one of four density categories and include prescribed language explaining that dense tissue can make cancers harder to detect on a mammogram and may raise the risk of developing breast cancer. When facilities employ imaging assessment categories or density descriptors, those terms must conform to the official MQSA lexicon and reporting requirements established in 21 CFR part 900. The U.S. Food and Drug Administration final rule published March 10, 2023, establishes these requirements. [1][2]

This contemporary refinement rests on a foundation laid more than three decades earlier. On October 27, 1992, President George H.W. Bush signed H.R. 6182, the Mammography Quality Standards Act, into law as Public Law 102-539. [12]

The signing statement captured the political tensions that had shaped the legislation. Bush opened with a public affirmation of the fight against breast cancer, specifically applauding Marilyn Quayle, whose mother had died of the disease, and declaring his administration's commitment to ensuring that every woman had access to affordable, high-quality mammograms. Almost immediately the tone shifted. The statement repeated a series of interpretive limitations: "I must note, however…," "Specifically, I do not interpret the language…," "Similarly, I do not view the language…," "I also do not interpret…." These clauses carefully circumscribed federal authority over appointments, state enforcement, and litigation. The dual voice reflected a bill forged between rising public demand for reliable early detection and institutional caution about expanding regulatory power. The Public Papers of the Presidents of the United States contain the complete text of the signing statement. [3]

Cultural Shift Opens the Door

The path to that moment began with cultural change in the mid-1970s. In September 1974 First Lady Betty Ford publicly disclosed her breast-cancer diagnosis and radical mastectomy, breaking a long silence that had treated the disease as a private shame. Her candor produced an immediate rise in examinations and diagnoses and helped normalize open discussion. The broader women's health movement of the 1970s and 1980s further challenged medical paternalism, insisting on information, second opinions, and patient agency. Archival materials from the Gerald R. Ford Presidential Library document the disclosure and its immediate effects. [4]

Into this environment stepped Nancy Brinker. After her sister Susan G. Komen died of breast cancer in 1980 at age 36, Brinker founded the Susan G. Komen Breast Cancer Foundation in 1982. Through Race for the Cure events, the pink ribbon, and sustained advocacy for insurance coverage of screening, the organization converted private grief into organized political pressure for reliable mammography. Organizational records maintained by Susan G. Komen confirm the founding timeline and early advocacy priorities. [5]

Science Documents the Gap

Scientific surveys soon quantified the gap between rising demand and technical performance. The FDA's Nationwide Evaluation of X-ray Trends (NEXT) program, beginning with its 1985 mammography survey of 232 facilities, documented substantial variation in image quality, radiation dose, equipment performance, and processing. Many facilities still used non-dedicated equipment. Later NEXT surveys in 1988 and 1992 recorded incremental gains, yet inconsistencies persisted. Conway and colleagues, reporting in Radiology in 1994, demonstrated a 34 percent improvement in acceptable phantom image quality scores between 1985 and 1992, accompanied by a 20 percent decrease in mean glandular dose, largely from the elimination of xeroradiography. [6]

Voluntary Accreditation Proves Insufficient

In 1987 the American College of Radiology launched a voluntary Mammography Accreditation Program. Technical leaders including R. Edward Hendrick, PhD, Priscilla F. Butler, MS, Lawrence W. Bassett, MD, Carl J. D'Orsi, MD, and Robert A. Smith, MD of the American Cancer Society developed peer-review criteria for equipment, personnel, image quality, and dose. Early first-attempt pass rates hovered near 70 percent, implying failure rates approaching 30 percent. Participation remained incomplete. By 1991 approximately half of an estimated 10,000 mammography units had applied, and only about one-quarter were fully accredited. Some practices accredited a single unit while advertising the entire operation as accredited. Parallel efforts to standardize reporting language that would become ACR BI-RADS© likewise saw only tentative early adoption. Destouet and colleagues summarized the first decade of the ACR program in the Journal of the American College of Radiology. [8] Government Accountability Office reports in 1990 and subsequent testimony documented weak quality-assurance programs and inadequate state oversight. Senate hearings in 1991–1992 described existing standards as confused and inadequate. [9][11]

Public Scrutiny Intensifies

Concurrent events heightened scrutiny of women's health. The 1992 silicone breast-implant controversy, culminating in an FDA moratorium, underscored regulatory gaps and the potential of implants to obscure mammographic tissue. Partial federal measures, including the Breast and Cervical Cancer Mortality Prevention Act of 1990 and Medicare coverage of screening mammography beginning in 1991, created limited footholds but left most facilities outside robust inspection.

Legislative Momentum Reaches Critical Mass

Senator Barbara Mikulski emerged as the principal congressional champion, joined by Representative John Dingell in the House and supported by bipartisan negotiation that included Senator Orrin Hatch's efforts to address administration concerns about regulatory burden. The final bill moved with unusual speed: introduced on October 6, 1992, passed by the House the same day under suspension of the rules, passed by the Senate the next day by voice vote, and signed on October 27. Congressional records confirm the legislative chronology. [10]

Rapid Implementation Follows

Implementation followed rapidly. The Secretary of Health and Human Services delegated authority to the FDA in June 1993. Interim regulations appeared in December 1993; certification became mandatory on October 1, 1994. Final regulations published in 1997 and effective in 1999 added greater specificity on personnel qualifications, equipment performance, quality-assurance programs, and reporting. Inside the agency, staff including Helen Barr, MD, and Charles Finder, MD, helped shape operational guidance that translated statutory requirements into workable standards. [1][2]

The subsequent record demonstrates durability. Early inspection cycles showed significant violation rates that declined steadily. Phantom image scores improved, radiation doses were brought under control, and serious noncompliance fell to low levels. Reauthorizations in 1998 and 2004 refined patient notification and administrative flexibility without altering the core architecture. The 2024 density-notification requirements represent the latest extension of the same principle: clear, standardized communication grounded in national quality standards. When facilities use ACR BI-RADS© categories for imaging assessments or breast density, those terms remain subordinate to the official MQSA lexicon established in 21 CFR part 900. [1][2]

A Durable Framework Still Operating

Over more than three decades, with mammography volumes now exceeding 40 million examinations annually, MQSA has been intricately responsible for safeguarding the mammography imaging quality and subsequent care of several hundred million women. MQSA is not a historical relic that once offered protection. It continues to deliver protection today as a robust, functioning program—the strongest and most comprehensive quality-oversight framework of any single diagnostic imaging modality in America's healthcare delivery system.

The operational implication is clear. Technical quality standards enforced by continuous federal certification, annual inspection, and mandatory accreditation remain uniquely robust. Interpretive quality and equitable access still vary and lie largely outside the original statutory architecture. Leadership must therefore decide whether incremental refinements such as density notification are sufficient, or whether the next structural revision of the only imaging modality with real federal teeth is now required.

---

References

1. US Food and Drug Administration. Mammography Quality Standards Act. Final rule. 88 Fed Reg 15126 (March 10, 2023). Effective September 10, 2024. federalregister.gov
2. US Food and Drug Administration. Mammography Quality Standards Act (MQSA) and MQSA Program. Updated 2026. fda.gov
3. Bush GHW. Statement on Signing the Mammography Quality Standards Act of 1992. Public Papers of the Presidents of the United States: George H. W. Bush (1992–1993, Book II). October 27, 1992:2031. govinfo.gov
4. Gerald R. Ford Presidential Library. Betty Ford breast cancer disclosure materials, September–October 1974. ford.blogs.archives.gov
5. Susan G. Komen. Organizational history and milestones, 1982–1992. komen.org
6. Conway BJ, Suleiman OH, Rueter FG, Antonsen RG, Slayton RJ. National survey of mammographic facilities in 1985, 1988, and 1992. Radiology. 1994;191(2):323-330. doi:10.1148/radiology.191.2.8153301
7. Hendrick RE. Standardization of image quality and radiation dose in mammography. Radiology. 1990;174(3):648-654. doi:10.1148/radiology.174.3.2305044
8. Destouet JM, Bassett LW, Yaffe MJ, Butler PF, Wilcox PA. The ACR's Mammography Accreditation Program: ten years of experience since MQSA. J Am Coll Radiol. 2005;2(7):585-594. jacr.org
9. US Government Accountability Office. Screening Mammography: Low-Cost Services Do Not Compromise Quality. GAO/HRD-90-32. January 10, 1990. gao.gov
10. US Congress. H.R. 6182 – Mammography Quality Standards Act of 1992. 102nd Cong. congress.gov
11. US Senate. Committee on Labor and Human Resources, Subcommittee on Aging. The Failure and Success of Current Mammography Practice. Hearing, October 24, 1991. S. Hrg. 102-385.
12. Mammography Quality Standards Act of 1992, Pub L No. 102-539, 106 Stat 3547. govinfo.gov